<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819479</url>
  </required_header>
  <id_info>
    <org_study_id>14-N0229</org_study_id>
    <nct_id>NCT02819479</nct_id>
  </id_info>
  <brief_title>Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)</brief_title>
  <acronym>LIBERTI</acronym>
  <official_title>Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norton Healthcare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kentucky</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norton Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the overall safety and efficacy of intra-arterial (IA) bevacizumab for the&#xD;
      treatment of radiation necrosis. A single 2.5 mg/kg dose of bevacizumab will be given&#xD;
      intra-arterially after osmotic blood-brain-barrier disruption.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND Radiation Necrosis: Stereotactic radiosurgery has become integral in treatment of&#xD;
      brain tumors and arteriovenous malformations (AVM). In up to 10% of cases, this can lead to&#xD;
      radiation necrosis (RN) with significant surrounding vasogenic edema and mass effect. Medical&#xD;
      treatment for RN includes steroids, vitamin E, pentoxiphylline, and hyperbaric oxygen. Up to&#xD;
      20% of cases however, are medically refractory and experience progressive neurological&#xD;
      decline and disabling headaches.&#xD;
&#xD;
      Surgical resection and laser interstitial thermal therapy (LITT) are sometimes used for&#xD;
      treatment of medically refractory radiation necrosis. These invasive options carry risks of&#xD;
      serious complications such as infection, seizures, neurological deficits, and hemorrhage, and&#xD;
      may have a failure rate as high as 39% in patients with radiation necrosis of the brain.&#xD;
&#xD;
      Bevacizumab: Bevacizumab (Avastin, Genentech BioOncology, South San Francisco, CA) is a&#xD;
      recombinant humanized version of a murine anti-human vascular endothelial growth factor&#xD;
      (VEGF) monoclonal antibody. Recently, bevacizumab was shown in a small randomized controlled&#xD;
      trial (n=14) to be effective in treatment of refractory radiation necrosis after radiation&#xD;
      therapy in brain tumors1. Patients received 7.5 mg/kg IV-Bevacizumab every 3 weeks for 4&#xD;
      cycles. All patients receiving Bevacizumab and none of the patients receiving placebo had&#xD;
      significant clinical and radiographic improvement.&#xD;
&#xD;
      PRE-CLINICAL DATA Role of vascular endothelial growth factor (VEGF) in radiation necrosis&#xD;
      VEGF has been implicated in the pathophysiology of radiation necrosis. Reactive astrocytes&#xD;
      immediately surrounding the necrotic core in RN are strongly VEGF-positive by&#xD;
      immunohistochemistry. It is postulated that radiation causes microvascular injury leading to&#xD;
      hypoxia. Hypoxia-induced VEGF up-regulation then drives an increase in vascular permeability,&#xD;
      leading to the extensive vasogenic edema seen in RN. Bevacizumab binds circulating VEGF&#xD;
      receptors with high specificity, blocking the down-stream signaling cascade.&#xD;
&#xD;
      CLINICAL DATA:&#xD;
&#xD;
      Bevacizumab was originally developed and tested as an anti-angiogenic treatment for various&#xD;
      solid tumors. More recently, IV-Bevacizumab was shown in a small, randomized controlled trial&#xD;
      (n=14) to be very effective in treatment of refractory radiation necrosis after radiation&#xD;
      therapy in brain tumors1. Patients received 7.5 mg/kg IV-Bevacizumab every 3 weeks for 4&#xD;
      cycles. All patients receiving Bevacizumab and none of the patients receiving placebo had&#xD;
      significant clinical and radiographic improvement. This improvement was durable at 10 months&#xD;
      in 8 of 11 patients (4 patients crossed over from the control group). There was however, a&#xD;
      very high rate of adverse events (60%), and major adverse events (30%). Major adverse events&#xD;
      included venous sinus thrombosis, pulmonary embolus, and aspiration pneumonia.&#xD;
&#xD;
      The investigators of the present study recently published a case series of two pediatric&#xD;
      patients with highly symptomatic steroid refractory radiation necrosis in the brain after&#xD;
      stereotactic radiosurgery for treatment of cerebral arteriovenous malformations3. Both&#xD;
      patients were refractory to all accepted medical therapies. Both were steroid dependent for a&#xD;
      prolonged period and severely cushingoid. Both had suffered a significant decline in quality&#xD;
      of life with severe headache and needed to withdraw from school. In both instances, the&#xD;
      patients made a remarkable progressive clinical and radiographic improvement after receiving&#xD;
      a single 2.5 mg/kg dose of intra-arterial bevacizumab, which was durable one-year later. To&#xD;
      increase bevacizumab penetration into the brain, the investigators used intra-arterial&#xD;
      Mannitol to disrupt the blood-brain barrier immediately prior to targeted intra-arterial drug&#xD;
      administration.&#xD;
&#xD;
      RATIONALE:&#xD;
&#xD;
      RATIONALE: CURRENT IV BEVACIZUMAB REGIMEN FOR RADIATION NECROSIS AND ITS ASSOCIATED&#xD;
      MORBIDITY:&#xD;
&#xD;
      Current IV-bevacizumab regimens use a dose of 7.5 mg/kg every 3 weeks for 4 cycles. There are&#xD;
      significant known side effects of bevacizumab including gastrointestinal perforation, deep&#xD;
      venous thrombosis, venous sinus thrombosis, pulmonary embolus, intracranial hemorrhage, wound&#xD;
      dehiscence, and severe hypertension. These complications are common to the anti-angiogenic&#xD;
      class of drugs and reflect systemic exposure to bevacizumab. In our initial clinical&#xD;
      experience, the investigators utilized a combination of intra-arterial (IA) route of delivery&#xD;
      and BBB disruption to reduce bevacizumab dose while maintaining efficacy. This is supported&#xD;
      by the durable clinical and radiographic response in our patients after a single 2.5 mg/kg&#xD;
      dose of bevacizumab. The investigators believed that this approach would reduce the incidence&#xD;
      of serious systemic toxicities compared to the IV-bevacizumab regimens (7.5-15 mg/kg every&#xD;
      2-3 weeks for several weeks to months).&#xD;
&#xD;
      There are multiple recent reports of patients with radiation necrosis who improved with&#xD;
      IV-bevacizumab, only to relapse months later. In fact 3/11 patients in the randomized&#xD;
      controlled trial discussed above required repeat treatment with IV-bevacizumab because of RN&#xD;
      symptom progression1. In contrast, the two patients in our series who received IA-bevacizumab&#xD;
      continue to show progressive clinical and radiographic improvement more than one year later.&#xD;
      The investigators believe that the increased penetration of bevacizumab into the brain&#xD;
      because of the intra-arterial administration after blood-brain barrier disruption results in&#xD;
      binding of virtually all VEGF molecules. The fact that the results are durable and&#xD;
      progressively improving suggests that massive blocking of VEGF activity could have stopped a&#xD;
      positive feedback loop of inflammation. Therefore, IA-bevacizumab may result in more&#xD;
      effective and durable control of radiation necrosis compared to traditional IV-bevacizumab&#xD;
      treatment.&#xD;
&#xD;
      RATIONALE: INTRA-ARTERIAL (IA) ROUTE OF BEVACIZUMAB ADMINISTRATION SIGNIFICANTLY INCREASES&#xD;
      DRUG DELIVERY TO THE BRAIN:&#xD;
&#xD;
      IA-therapy decreases volume dilution of the drug in the circulation and reduces first-pass&#xD;
      degradation via proteolytic catabolism, resulting in higher drug delivery to target brain&#xD;
      tissue. Super-selective IA-injection of 99mTc-HMPAO (CeretecÂ®) into human cerebral arteries&#xD;
      achieves a concentration of radiotracer in brain tissue 50 times higher than with IV&#xD;
      injection. In clinical studies of cerebral chemotherapy, the concentration delivered to the&#xD;
      tumor by using intra-arterial injection versus intravenous administration of chemotherapeutic&#xD;
      agents was five times higher with hydrosoluble drugs and up to 50 times higher with&#xD;
      liposoluble drugs. The investigators will infuse bevacizumab in the artery that supplies the&#xD;
      territory affected by RN, such as cervical internal carotid artery and/or cervical vertebral&#xD;
      artery.&#xD;
&#xD;
      RATIONALE: BLOOD-BRAIN-BARRIER BREAKDOWN PRIOR TO INTRA-ARTERIAL THERAPY FURTHER ENHANCES&#xD;
      DRUG DELIVERY TO THE BRAIN:&#xD;
&#xD;
      The blood-brain-barrier is a selective permeability barrier that block entry of many drugs&#xD;
      into the brain. Bevacizumab is a monoclonal antibody with a high molecular weight (149 kDa).&#xD;
      There is convincing evidence in the literature that the concentration in the brain of high&#xD;
      molecular weight molecules can be significantly increased after osmotic BBB disruption.&#xD;
      Several tumor clinical trials have shown that localization of monoclonal antibodies to the&#xD;
      brain is poor without BBB disruption (0.0006%-0.0043% of the injected dose/g of tumor). There&#xD;
      is also evidence of a 20-fold increase in permeability to immunoreactive IgM Mab with BBB&#xD;
      disruption in rats. The investigators believe that using blood-brain-barrier disruption&#xD;
      significantly increases delivery of Bevacizumab to the affected brain. The investigators will&#xD;
      use the protocol described by Neuwelt and colleagues, using infusion of 25% Mannitol over 30&#xD;
      seconds. This protocol has been shown to temporarily disrupt the blood brain barrier, peaking&#xD;
      at 15 minutes and dissipating in 4 hours. IA-chemotherapy following BBBD has been shown to be&#xD;
      feasible and safe across multiple centers with low incidence of complications27. The efficacy&#xD;
      and safety profile was reproducible across multiple centers. In fact, safety of this protocol&#xD;
      has been established in more than 6000 patients treated worldwide with BBBD for&#xD;
      intra-arterial chemotherapy infusion. The main possible complication is seizure, which occurs&#xD;
      in &lt;6% of cases. It is important to note that these seizures generally occurred in patients&#xD;
      with widespread malignant pathology such as Glioblastoma and CNS lymphoma who were treated&#xD;
      with very toxic chemotherapy agents immediately after BBBD. Recent refinements to the osmotic&#xD;
      BBBD protocol have incorporated the use of general anesthesia, as well as prophylaxis with an&#xD;
      anti-epileptic agent and Valium to reduce seizure threshold and the chance of seizures.&#xD;
&#xD;
      SAFETY OF CEREBRAL INTRA-ARTERIAL BEVACIZUMAB TREATMENT:&#xD;
&#xD;
      Safety of IA-Bevacizumab treatment after hyperosmotic BBBD was recently established in a&#xD;
      series of malignant glioma patients. This was done through super-selective injection of&#xD;
      intracranial tumor arterial pedicles for purpose of anti-tumor effects. Dose-escalation was&#xD;
      performed from 2 mg/kg to 15 mg/kg without reaching maximal tolerated dose. There was a&#xD;
      significant decrease in the contrast enhancing and FLAIR signal characteristics of the tumor&#xD;
      and surrounding brain at one month after treatment. Overall toxicity for this cohort was&#xD;
      comparable to previous reports for IV Bevacizumab therapy. Specifically, hyperosmotic&#xD;
      BBB-breakdown followed by IA-Bevacizumab administration did not cause any direct&#xD;
      neurotoxicity; there were no cases of intracranial hemorrhage. Multiple other reports of BBBD&#xD;
      followed by intra-arterial bevacizumab treatment for other pathologies such as vestibular&#xD;
      schwannoma, ependymoma, and malignant brainstem glioma have also demonstrated good safety&#xD;
      profile with no obvious neurotoxicity.&#xD;
&#xD;
      TREATMENT PLAN:&#xD;
&#xD;
      VASCULAR ACCESS, CEREBRAL ANGIOGRAM, AND OSMOTIC BLOOD-BRAIN-BARRIER DISRUPTION:&#xD;
&#xD;
      The investigators will use the protocol described by Neuwelt and colleagues, using infusion&#xD;
      of 25% Mannitol over 30 seconds. The safety of this protocol has been established in more&#xD;
      than 6000 patients treated worldwide with BBBD for intra-arterial chemotherapy infusion.&#xD;
&#xD;
      The patients are to be premedicated with 6 mg Dexamethasone and 1000 mg Keppra. General&#xD;
      endotracheal anesthesia will be induced. The femoral artery will be accessed using the&#xD;
      Seldinger technique. A 5-French diagnostic catheter will be used to catheterize the cervical&#xD;
      internal carotid artery ipsilateral to the area of radiation necrosis. Baseline internal&#xD;
      carotid angiogram will be performed.&#xD;
&#xD;
      The anesthesiologist will be instructed to maintain SBP &gt;120 or at pre-operative baseline,&#xD;
      whichever value is higher. This is important for efficient bulk flow of drug through the&#xD;
      blood brain barrier opening. The catheter is positioned at C1-2 level in the cervical&#xD;
      internal carotid artery and C6-7 for a vertebral artery infusion. Optimal rate of Mannitol&#xD;
      infusion will be determined by performing injection of contrast at 4 ml/sec for 3 seconds&#xD;
      into vessel. If there is no reflux of contrast into the external carotid artery, the&#xD;
      injection rate injection will be increased by 2 ml/sec to maximum of 12 ml/sec. The lowest&#xD;
      rate at which there is reflux into the external carotid artery will be chosen (the rate to&#xD;
      just exceed cerebral blood flow.&#xD;
&#xD;
      Next, 5 mg IV Valium and 0.2 mg IV Atropine are to be administered. Warm (37 degrees Co) 25%&#xD;
      Mannitol is filtered through a 5-micron filter, and then infused into the ipsilateral&#xD;
      cervical carotid artery at the rate determined above for a total of 30 seconds.&#xD;
&#xD;
      INTRA-ARTERIAL BEVACIZUMAB ADMINISTRATION:&#xD;
&#xD;
      Test injection of contrast will be done in the artery. If there is any evidence of&#xD;
      catheter-induced vasospasm, the catheter may be withdrawn more proximally within the artery.&#xD;
      Repeat test injection of contrast will be done to document resolution of vasospasm. Within 5&#xD;
      minutes of Mannitol infusion, 2.5 mg/kg bevacizumab in a volume of 100 ml will be&#xD;
      administered into the artery over 10 minutes. Repeat angiogram will be performed to document&#xD;
      BBBD, as well as to rule out thromboembolic phenomenon.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 23, 2016</start_date>
  <completion_date type="Actual">June 6, 2019</completion_date>
  <primary_completion_date type="Actual">June 6, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Radiation Necrosis and Cerebral Edema After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab)</measure>
    <time_frame>Baseline (before treatment), and 3 months and 12 months after single dose intra-arterial Avastin (bevacizumab)</time_frame>
    <description>Imaging response to therapy will be quantitatively assessed on MRI using volumetric analysis. Regions of T2 and FLAIR prolongation above contralateral white matter will be calculated and quantified in cubic centimeters. Region of interest (ROI) will be created using a semi-automated, thresholding and region-growing technique. Enhancement of the lesion will be calculated using similar volumetric ROI analysis with a contrast threshold of 40% above background and measured in cubic centimeters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Headache Associated Morbidity Measured With MIDAS TOTAL SCORE After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) Will be Measured.</measure>
    <time_frame>Baseline (before treatment), and 6 weeks, 3 months, 6 months, 9 months, and 12 months after single dose intra-arterial Avastin (bevacizumab)</time_frame>
    <description>We will determine how severely headache affect the patient's life before and after treatment by performing the Migraine Disability Assessment (MIDAS) questionnaire. MIDAS TOTAL SCORE is the sum of Items 1 through 5. A Total Score of 0-5 signifies little or no disability, score of 6-10 signifies mild disability, score of 11-20 signifies moderate disability, and score of 21+ signifies severe disability. The theoretical maximum score would be 450.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Headache Associated Morbidity Measured With MIDAS DAYS of HEADACHE After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) Will be Measured.</measure>
    <time_frame>Baseline (before treatment), and 6 weeks, 3 months, 6 months, 9 months, and 12 months after single dose intra-arterial Avastin (bevacizumab)</time_frame>
    <description>We will determine how severely headache affect the patient's life before and after treatment by performing the Migraine Disability Assessment (MIDAS) questionnaire. MIDAS DAYS of HEADACHE is Item 6 of the questionnaire which sums total number of days the patient had headache symptoms over the past 3 months regardless of headache severity or resultant disability. Min score of 0 days is the best possible score. Max Score of 90 days is worse possible score, meaning the patient experienced headache pain every day over past 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Headache Associated Morbidity Measured With MIDAS PAIN LEVEL After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) Will be Measured.</measure>
    <time_frame>Baseline (before treatment), and 6 weeks, 3 months, 6 months, 9 months, and 12 months after single dose intra-arterial Avastin (bevacizumab)</time_frame>
    <description>We will determine how severely headache affect the patient's life before and after treatment by performing the Migraine Disability Assessment (MIDAS) questionnaire. MIDAS PAIN LEVEL is Item 7 which rates the 3-month average headache PAIN LEVEL on scale from 0 to 10 where 0 = no pain at all, and 10 = pain as bad as it can be.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Headache Measured With Headache Impact Test (HIT-6) After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab)</measure>
    <time_frame>Baseline (before treatment), and 6 weeks, 3 months, 6 months, 9 months, and 12 months after single dose intra-arterial Avastin (bevacizumab)</time_frame>
    <description>Quantitative change in headache will be assessed by performing the Headache Impact Test (HIT-6), which is a fixed-length 6-item questionnaire. The score for this questionnaire can range from 36 to 78, with 36 indicating minimum headache impact and the max score of 78 indicating worst possible headache impact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status After a Single Treatment of Low Dose Intra-arterial Bevacizumab</measure>
    <time_frame>Baseline (before treatment), Day 1, and at 3 months, and 12 months after single dose intra-arterial Avastin (bevacizumab)</time_frame>
    <description>Quantitative change in functional status will be assessed by performing Karnofsky Performance Status Scale (KPS). The KPS score can range from 0 to 100 where 0 is dead and 100 is fully alive and normal with no complaints and no evidence of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Steroid Usage After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab)</measure>
    <time_frame>12 months prior to single dose of IA bevacizumab; 12 months following single dose of IA bevacizumab</time_frame>
    <description>To assess the utility of intra-arterial (IA) bevacizumab treatment in allowing decreased steroid usage, total cumulative days of steroid usage were compared between the 12 months PRIOR TO and the 12 months IMMEDIATELY FOLLOWING IA bevacizumab. Days of steroid usage were tabulated via medical history and chart review at the baseline visit for the 12 months prior to IA bevacizumab and post-treatment on days 0 and 1, week 6, and months 3, 6, 9 and 12 for the 12 month total after IA bevacizumab treatment. Excluding topical steroid preparations, all days of enteral or parenteral steroid intake of any dose were included in the cumulative summation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Neurocognitive Change After Intra-arterial Bevacizumab</measure>
    <time_frame>Baseline (before bevacizumab), and 3 months and 12 months after single dose intra-arterial Avastin (bevacizumab)</time_frame>
    <description>In order to investigate post-operative changes in Neurocognitive performance after intra-arterial bevacizumab, patients who consented underwent formal neuropsychological battery testing. Sixteen subtests from the Neuropsychological Assessment Battery (Stern &amp; White, PAR Inc.) were chosen for brevity, sensitivity, and due to the wide range of available normative data (ages 18-97). For each subtest, T-score = 50 is the normative mean with SD = 10. Thus T-scores of 40-60 are within one standard deviation of the mean and are considered generally normal. Scores increasingly below 40 indicate decreased neurocognitive performance compared to healthy demographically matched persons. Scores significantly above 60 indicate increase neurocognitive performance compared to healthy demographically matched persons.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Radiation Necrosis</condition>
  <arm_group>
    <arm_group_label>Low-dose Intra-arterial Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intra-arterial targeted dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25% Mannitol</intervention_name>
    <description>Route of administration:&#xD;
In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.</description>
    <arm_group_label>Low-dose Intra-arterial Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose Intra-arterial Bevacizumab</intervention_name>
    <description>Route of administration:&#xD;
In this study, the second step of the treatment will be administering intra-arterial targeted bevacizumab into the appropriate cervical artery.</description>
    <arm_group_label>Low-dose Intra-arterial Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must have radiation necrosis based on radiographic evidence defined as:&#xD;
&#xD;
          -  Increased T1 contrast enhancement in the radiated area with central hypointensity&#xD;
&#xD;
          -  Increased surrounding vasogenic edema on FLAIR MRI images&#xD;
&#xD;
          -  The underlying lesion prompting the radiation can include: Benign lesions such as AVM,&#xD;
             Meningioma, schwannoma, trigeminal neuralgia: No biopsy is necessary&#xD;
&#xD;
          -  Radiation necrosis must be symptomatic, including either severe headache, seizures, or&#xD;
             neurological deficits.&#xD;
&#xD;
          -  Radiation necrosis must be refractory to steroid treatment; defined as failing a&#xD;
             3-week steroid regiment or not tolerating steroids because of side effects. Beyond 3&#xD;
             weeks, the side effects of steroid therapy worsen rapidly. The patient may receive&#xD;
             other therapies such as Vitamine E, Pentoxyfylline, and hyperbaric oxygen during the&#xD;
             trial.&#xD;
&#xD;
        Other inclusion criteria include:&#xD;
&#xD;
          -  Age &gt;18 years.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
          -  Both men and women and members of all races and ethnic groups are eligible for this&#xD;
             trial.&#xD;
&#xD;
          -  Karnofsky Performance Status &gt; or = 70%.&#xD;
&#xD;
          -  Life expectancy of greater than 3 months.&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
        leukocytes greater than equal to1,500/mcL platelets greater than equal to 85,000/mcL&#xD;
        creatinine less than equal to 1.8 mg/dl&#xD;
&#xD;
        â¢Birth Control: The effects of Bevacizumab on the developing human fetus are unknown. For&#xD;
        this reason, women of childbearing potential and men must agree to use adequate&#xD;
        contraception (hormonal or barrier method of birth control; abstinence) prior to study&#xD;
        entry and for the duration of study participation. Should a woman become pregnant or&#xD;
        suspect she is pregnant while participating in this study, she should inform her treating&#xD;
        physician immediately. Women of childbearing age will have a urine pregnancy test&#xD;
        immediately before each IA Bevacizumab treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not be started on any other investigational agents during the course of&#xD;
             this trial. They may however continue previous medical regiments aimed for treatment&#xD;
             of radiation necrosis. These include steroids, vitamin E, pentoxiphylline, and&#xD;
             hyperbaric oxygen. We feel that these treatments are generally ineffectual and would&#xD;
             not confound the results.&#xD;
&#xD;
          -  Malignant brain tumor&#xD;
&#xD;
          -  Concomitant use of anticoagulation agents including Coumadin, anticoagulation dose&#xD;
             Lovenox or Arixtra. Aspirin is acceptable.&#xD;
&#xD;
          -  Active bleeding or pathological condition that carries high risk of bleeding.&#xD;
&#xD;
          -  Abdominal fistula, abscess, or gastrointestinal tract perforation 28 days of study&#xD;
             entry.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Any major surgery in the prior 4 weeks. Also any major surgery expected to be&#xD;
             performed in the ensuing 4 weeks after treatment.&#xD;
&#xD;
          -  Pregnant women are excluded from this study because Bevacizumab is expected to disrupt&#xD;
             angiogenesis during pregnancy with the potential for teratogenic or abortive effects.&#xD;
             Because there is an unknown but potential risk for adverse events in nursing infants&#xD;
             secondary to treatment of the mother with Bevacizumab, breastfeeding should be&#xD;
             discontinued if the mother is treated with Bevacizumab.&#xD;
&#xD;
          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of&#xD;
             the potential for pharmacokinetic interactions with Bevacizumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shervin R Dashti, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norton Healthcare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Justin Fraser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Brownsboro Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <results_first_submitted>October 16, 2020</results_first_submitted>
  <results_first_submitted_qc>June 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2021</results_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Norton Healthcare</investigator_affiliation>
    <investigator_full_name>Shervin Dashti, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Radiation necrosis</keyword>
  <keyword>Radiation adverse event</keyword>
  <keyword>Intra-arterial chemotherapy</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Blood brain barrier disruption</keyword>
  <keyword>Blood brain barrier breakdown</keyword>
  <keyword>Arteriovenous malformation</keyword>
  <keyword>Stereotactic radiosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02819479/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02819479/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adults recruited from outpatient medical clinics at 2 academic medical centers (5 subjects per center) between Nov 2016 and Jan 2018. Enrollment was closed once 10 adult subjects were enrolled.</recruitment_details>
      <pre_assignment_details>This was a single-arm study. There was no wash out or run-in period after enrollment. There was no assignment to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low-dose Intra-arterial Bevacizumab</title>
          <description>A single intra-arterial dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.&#xD;
25% Mannitol: Route of administration: In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.&#xD;
Low-dose Intra-arterial Bevacizumab: Route of administration:&#xD;
In this study, the second step of the treatment will be administering intra-arterial bevacizumab into the appropriate cervical artery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8">2 subjects experienced recurrence of radiation necrosis requiring intervention at approx. month 11.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low-dose Intra-arterial Avastin (Bevacizumab)</title>
          <description>A single intra-arterial dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.&#xD;
25% Mannitol: Route of administration: In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.&#xD;
Low-dose Intra-arterial Bevacizumab: Route of administration:&#xD;
In this study, the second step of the treatment will be administering intra-arterial bevacizumab into the appropriate cervical artery.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at enrollment, years</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MRI of Brain: volume of radiation necrosis</title>
          <units>cubic centimeters, or cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MRI of Brain: volume of edema</title>
          <units>cubic centimeters, or cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.8" spread="95.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Headache severity via Migraine Disability Assessment (MIDAS) TOTAL SCORE</title>
          <description>MIDAS (Migraine Disability Assessment) is a 7-item tool that measures how severely headaches prevented or interfered with normal activity over the past 3 months. For each item 1 through 5 the min score=0 days, max score=90 days. The MIDAS TOTAL SCORE sums items 1 - 5 only. TOTAL SCORE of 0-5 indicates little or no disability. Total Score of 6-10 indicates mild disability. Total Score of 11-20 indicates moderate disability. Total score of 21+ indicates severe disability. Theoretical Max Total Score is 450 days.</description>
          <units>units on a scale from 0 to 450</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.7" spread="110.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DAYS of Headache via Migraine Disability Assessment (MIDAS)</title>
          <description>MIDAS (Migraine Disability Assessment) questionnaire is a 7-item tool that measures how severely headaches prevented or interfered with normal activity over the past 3 months. MIDAS DAYS of HEADACHE is Item 6 of the questionnaire which sums total number of days the patient had headache symptoms over the past 3 months regardless of headache severity or resultant disability. Min score of 0 days is the best possible score. Max Score of 90 days is worse possible score, meaning the patient experienced headache pain every day over past 3 months.</description>
          <units>Days of headache over past 3 months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Headache PAIN LEVEL via Migraine Disability Assessment (MIDAS)</title>
          <description>MIDAS (Migraine Disability Assessment) is a 7-item tool that measures how severely headaches prevented or interfered with normal activity over the past 3 months. Item 7 rates the 3-month average headache PAIN LEVEL on scale from 0 to 10 where 0 = no pain at all, and 10 = pain as bad as it can be.</description>
          <units>units on a scale from 0 to 10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Headache severity via Headache Impact Test (HIT-6)</title>
          <description>The Headache Impact Test-6 is a tool used to measure the impact headaches have on a patient's ability to function in their normal daily life. This 6-item questionnaire was designed to help patients describe and communicate the way they feel and what they cannot do because of their headaches. For each item, patients must select one answer: never, rarely, sometimes, very often, or always. Scores range from min of 36 indicating minimum headache impact, to a max of 78 indicating worst possible headache impact. A score of 60 or more indicates headaches having a very severe impact on daily life.</description>
          <units>units on a scale from 36 - 78</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cumulative Days of Steroid use during 12 months Pre-Bevacizumab</title>
          <description>Total cumulative days of steroid usage were compared between the 12 months prior to and the 12 months immediately following targeted IA-bevacizumab. Days of steroid usage was tabulated via medical history and chart review at the baseline visit, and post-treatment on days 0 and 1, week 6, and months 3, 6, 9 and 12. Excluding topical steroid preparations, all days of enteral or parenteral steroid intake of any dose were included in the cumulative summation.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status Scale</title>
          <description>The Karnofsky Performance Status Scale allows patients to be classified as to their functional impairment. The lower the score, the worse the survival for most serious illnesses. Scores range from 0% to 100% where 100%=Normal with no complaints, no evidence of disease. 90%=Able to carry on normal activity; minor signs or symptoms of disease. 80%=Normal activity with effort; some signs or symptoms of disease. 70% = cares for self; unable to carry on normal activity or to do active work. 60%=Requires occasional assistance, but is able to care for most of his personal needs and 0%=Dead.</description>
          <units>% on Karnofsky scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.0" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Digits Forward via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically adjusted, normalized battery of tests which measure neurocognitive function. The Digits Forward module generates T scores which indicate the degree to which immediate auditory attention is higher or lower than that of healthy demographically matched individuals in the normative sample. T-score of 50 is the mean and is considered normal. Scores significantly below 40 indicate decreased auditory attention. Scores significantly above 60 indicate better auditory attention than healthy demographically matched persons.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Digits Backward via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically adjusted, normalized battery of tests which measure neurocognitive function. The Digits Backward module generates T scores which indicate the degree to which auditory working memory is stronger or weaker than that of a healthy demographically matched individual in the normative sample. T-score of 50 is equal to the mean and is considered normal. Scores significantly below 40 indicate decreased performance. Scores significantly above 60 indicate stronger ability compared to healthy demographically matched persons.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Numbers and Letters Speed via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically adjusted normalized battery of tests which measure neurocognitive function. Numbers &amp; Letters Speed module is an excellent general indicator of speed and efficiency of information processing. T scores indicate the degree to which info processing speed differs from that of healthy demographically matched individuals. T-scores of 40-60 are within 1 SD of the mean (50) and are considered normal. Scores below 40 indicate decreased processing speed. Scores above 60 indicate more rapid processing speed.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.2" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Numbers and Letters Errors via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically normalized battery of tests of neurocognitive function. Numbers &amp; Letters ERRORS module measures the extent of errorful processing. Errorful processing is considered &quot;inefficient&quot;. T scores indicate the degree to which processing efficiency differs from that of healthy demographically matched individuals. T-score of 50 is the mean. Scores significantly below 40 indicate decreased performance. Scores significantly above 60 indicate stronger ability compared to healthy demographically matched persons.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Numbers and Letters Efficiency via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically normalized battery of tests of neurocognitive function. Numbers &amp; Letters EFFICIENCY module compares error detection to time. Greater &quot;efficiency&quot; defined as minimal errors during rapid processing. Slow, errorful processing is considered &quot;inefficient&quot;. T scores indicate the degree to which processing efficiency differs from that of healthy demographically matched individuals. T-score of 50 is the mean. Scores below 40 indicate decreased info processing efficiency. Scores above 60 indicate more efficient processing.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.0" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Naming via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically normalized battery of tests of neurocognitive function. Naming module measures language processing. Errorful naming is considered inefficient language processing. T scores indicate the degree to which language processing differs from that of healthy demographically matched individuals. T-score of 50 is the mean. Scores significantly below 40 indicate decreased performance. Scores significantly above 60 indicate stronger ability compared to healthy demographically matched persons.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.6" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>List Learning List Immediate Recall via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically normalized battery of tests of neurocognitive function. The List Learning List Immediate Recall module is one measure of short term memory. T scores indicate the degree to which short term memory differs from that of healthy demographically matched individuals. T-score of 50 is the mean. Scores significantly below 40 indicate decreased performance. Scores significantly above 60 indicate stronger ability compared to healthy demographically matched persons.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>List Learning List Long Delayed Recall via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically normalized battery of tests of neurocognitive function. The List Learning List Long Delayed Recall module is one measure of long term memory. T scores indicate the degree to which long term memory differs from that of healthy demographically matched individuals. T-score of 50 is the mean. Scores significantly below 40 indicate decreased performance. Scores significantly above 60 indicate stronger ability compared to healthy demographically matched persons.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Shape Learning Immediate Recognition via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically normalized battery of tests of neurocognitive function. The Shape Learning Immediate Recognition module is another measure of short term memory. T scores indicate the degree to which short term memory differs from that of healthy demographically matched individuals. T-score of 50 is the mean. Scores significantly below 40 indicate decreased performance. Scores significantly above 60 indicate stronger ability compared to healthy demographically matched persons.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Shape Learning Delayed Recognition via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically normalized battery of tests of neurocognitive function. The Shape Learning Delayed Recognition module is another measure of long term memory. T scores indicate the degree to which long term memory differs from that of healthy demographically matched individuals. T-score of 50 is the mean. Scores significantly below 40 indicate decreased performance. Scores significantly above 60 indicate stronger ability compared to healthy demographically matched persons.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.3" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Story Learning Phrase Unit Immediate Recall via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically normalized battery of tests of neurocognitive function. The Story Learning Phrase Unit Immediate Recall module is another measure of short term memory. T scores indicate the degree to which short term memory differs from that of healthy demographically matched individuals. T-score of 50 is the mean. Scores significantly below 40 indicate decreased performance. Scores significantly above 60 indicate stronger ability compared to healthy demographically matched persons.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Story Learning Phrase Unit Delayed Recall via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically normalized battery of tests of neurocognitive function. The Story Learning Phrase Unit Delayed Recall module is another measure of long term memory. T scores indicate the degree to which long term memory differs from that of healthy demographically matched individuals. T-score of 50 is the mean. Scores significantly below 40 indicate decreased performance. Scores significantly above 60 indicate stronger ability compared to healthy demographically matched persons.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.7" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Design Construction via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically normalized battery of tests of neurocognitive function. Design Construction module is one measure of visuospatial processing. T scores indicate the degree to which visuospatial processing differs from that of healthy demographically matched individuals. T-score of 50 is the mean. Scores significantly below 40 indicate decreased performance. Scores significantly above 60 indicate stronger ability compared to healthy demographically matched persons.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mazes via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically normalized battery of tests of neurocognitive function. Mazes module is one measure of executive functioning. T scores indicate the degree to which executive functioning differs from that of healthy demographically matched individuals. T-score of 50 is the mean. Scores significantly below 40 indicate decreased performance. Scores significantly above 60 indicate stronger ability compared to healthy demographically matched persons.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Categories via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically normalized battery of tests of neurocognitive function. Categories module is another measure of executive functioning. T scores indicate the degree to which executive functioning differs from that of healthy demographically matched individuals. T-score of 50 is the mean. Scores significantly below 40 indicate decreased performance. Scores significantly above 60 indicate stronger ability compared to healthy demographically matched persons.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Word Generation via Neuropsychological Assessment Battery</title>
          <description>The Neuropsychological Assessment Battery is a comprehensive, demographically normalized battery of tests of neurocognitive function. The Word Generation module is another measure of executive functioning. T scores indicate the degree to which executive functioning differs from that of healthy demographically matched individuals. T-score of 50 is the mean. Scores significantly below 40 indicate decreased performance. Scores significantly above 60 indicate stronger ability compared to healthy demographically matched persons.</description>
          <units>T score with Mean=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.0" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Full Scale Intelligence Quotient (FSIQ) via Wechsler Test of Adult Reading</title>
          <description>The Wechsler Test of Adult Reading is a test of cognitive ability. The full scale intelligence quotient (FSIQ) estimate was obtained at Baseline to provide an estimate of premorbid cognitive functioning and to serve as a covariate for neurocognitive analyses. FSIQ population mean =100, SD = 15. By convention scores 130- 210 are very superior; 120-129 superior; 110-119 high average. Scores 90-109 are considered to be in the &quot;average&quot; range. Scores 80-89 are low average; 70-79 borderline; 28-69 are classified as extremely low.</description>
          <units>units on a scale from 28 to 210</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95.8" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Radiation Necrosis and Cerebral Edema After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab)</title>
        <description>Imaging response to therapy will be quantitatively assessed on MRI using volumetric analysis. Regions of T2 and FLAIR prolongation above contralateral white matter will be calculated and quantified in cubic centimeters. Region of interest (ROI) will be created using a semi-automated, thresholding and region-growing technique. Enhancement of the lesion will be calculated using similar volumetric ROI analysis with a contrast threshold of 40% above background and measured in cubic centimeters.</description>
        <time_frame>Baseline (before treatment), and 3 months and 12 months after single dose intra-arterial Avastin (bevacizumab)</time_frame>
        <population>10 adult subjects presented with medically refractory radiation necrosis of the brain and disabling headache. All were treated with steroids prior to study enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Intra-arterial Avastin (Bevacizumab)</title>
            <description>A single intra-arterial dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.&#xD;
25% Mannitol: Route of administration: In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.&#xD;
Low-dose Intra-arterial bevacizumab: Route of administration:&#xD;
In this study, the second step of the treatment will be administering intra-arterial bevacizumab into the appropriate cervical artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Radiation Necrosis and Cerebral Edema After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab)</title>
          <description>Imaging response to therapy will be quantitatively assessed on MRI using volumetric analysis. Regions of T2 and FLAIR prolongation above contralateral white matter will be calculated and quantified in cubic centimeters. Region of interest (ROI) will be created using a semi-automated, thresholding and region-growing technique. Enhancement of the lesion will be calculated using similar volumetric ROI analysis with a contrast threshold of 40% above background and measured in cubic centimeters.</description>
          <population>10 adult subjects presented with medically refractory radiation necrosis of the brain and disabling headache. All were treated with steroids prior to study enrollment.</population>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vol EDEMA at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8" spread="95.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vol EDEMA at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" spread="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vol EDEMA at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" spread="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vol Radiation Necrosis at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vol Radiation Necrosis at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vol Radiation Necrosis at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>CHANGE IN VOLUME OF RADIATION NECROSIS: To explore durability of radiographic responses, we invoked a linear mixed model in which we addressed heterogeneity of time points by fitting the most appropriate model among compound symmetry, Huyhn-Felt structure, and an unstructured covariance matrix (multivariate analysis of variance).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>F(1,14) = 8.29</method_desc>
            <param_type>eta^2</param_type>
            <param_value>0.37</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>CHANGE IN VOLUME OF CEREBRAL EDEMA: To explore durability of radiographic responses, we invoked a linear mixed model in which we addressed heterogeneity of time points by fitting the most appropriate model among compound symmetry, Huyhn-Felt structure, and an unstructured covariance matrix (multivariate analysis of variance).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>F(1,14) = 3.29</method_desc>
            <param_type>eta^2</param_type>
            <param_value>0.19</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Headache Associated Morbidity Measured With MIDAS TOTAL SCORE After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) Will be Measured.</title>
        <description>We will determine how severely headache affect the patient's life before and after treatment by performing the Migraine Disability Assessment (MIDAS) questionnaire. MIDAS TOTAL SCORE is the sum of Items 1 through 5. A Total Score of 0-5 signifies little or no disability, score of 6-10 signifies mild disability, score of 11-20 signifies moderate disability, and score of 21+ signifies severe disability. The theoretical maximum score would be 450.</description>
        <time_frame>Baseline (before treatment), and 6 weeks, 3 months, 6 months, 9 months, and 12 months after single dose intra-arterial Avastin (bevacizumab)</time_frame>
        <population>10 adult subjects presented with medically refractory radiation necrosis of the brain and disabling headache.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Intra-arterial Avastin (Bevacizumab)</title>
            <description>A single intra-arterial dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.&#xD;
25% Mannitol: Route of administration: In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.&#xD;
Low-dose Intra-arterial bevacizumab: Route of administration:&#xD;
In this study, the second step of the treatment will be administering intra-arterial bevacizumab into the appropriate cervical artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Headache Associated Morbidity Measured With MIDAS TOTAL SCORE After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) Will be Measured.</title>
          <description>We will determine how severely headache affect the patient's life before and after treatment by performing the Migraine Disability Assessment (MIDAS) questionnaire. MIDAS TOTAL SCORE is the sum of Items 1 through 5. A Total Score of 0-5 signifies little or no disability, score of 6-10 signifies mild disability, score of 11-20 signifies moderate disability, and score of 21+ signifies severe disability. The theoretical maximum score would be 450.</description>
          <population>10 adult subjects presented with medically refractory radiation necrosis of the brain and disabling headache.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MIDAS TOTAL at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7" spread="110.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS TOTAL at 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7" spread="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS TOTAL at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS TOTAL at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" spread="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS TOTAL at 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" spread="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS TOTAL at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>To explore durability of clinical response, Migraine Disability Assessment (MIDAS) TOTAL SCORES were analyzed using a linear mixed model in which we addressed heterogeneity of time points by fitting the most appropriate model among compound symmetry, Huyhn Felt structure, and an unstructured covariance matrix (multivariate analysis of variance)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>F(5,34) = 2.74</method_desc>
            <param_type>eta^2</param_type>
            <param_value>0.29</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Headache Associated Morbidity Measured With MIDAS DAYS of HEADACHE After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) Will be Measured.</title>
        <description>We will determine how severely headache affect the patient's life before and after treatment by performing the Migraine Disability Assessment (MIDAS) questionnaire. MIDAS DAYS of HEADACHE is Item 6 of the questionnaire which sums total number of days the patient had headache symptoms over the past 3 months regardless of headache severity or resultant disability. Min score of 0 days is the best possible score. Max Score of 90 days is worse possible score, meaning the patient experienced headache pain every day over past 3 months.</description>
        <time_frame>Baseline (before treatment), and 6 weeks, 3 months, 6 months, 9 months, and 12 months after single dose intra-arterial Avastin (bevacizumab)</time_frame>
        <population>10 adult subjects presented with medically refractory radiation necrosis of the brain and disabling headache.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Intra-arterial Avastin (Bevacizumab)</title>
            <description>A single intra-arterial dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.&#xD;
25% Mannitol: Route of administration: In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.&#xD;
Low-dose Intra-arterial bevacizumab: Route of administration:&#xD;
In this study, the second step of the treatment will be administering intra-arterial bevacizumab into the appropriate cervical artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Headache Associated Morbidity Measured With MIDAS DAYS of HEADACHE After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) Will be Measured.</title>
          <description>We will determine how severely headache affect the patient's life before and after treatment by performing the Migraine Disability Assessment (MIDAS) questionnaire. MIDAS DAYS of HEADACHE is Item 6 of the questionnaire which sums total number of days the patient had headache symptoms over the past 3 months regardless of headache severity or resultant disability. Min score of 0 days is the best possible score. Max Score of 90 days is worse possible score, meaning the patient experienced headache pain every day over past 3 months.</description>
          <population>10 adult subjects presented with medically refractory radiation necrosis of the brain and disabling headache.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MIDAS DAYS of HEADACHE at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS DAYS of HEADACHE at 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS DAYS of HEADACHE at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS DAYS of HEADACHE at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS DAYS of HEADACHE at 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS DAYS of HEADACHE at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>To explore durability of clinical response, Migraine Disability Assessment (MIDAS) DAYS OF HEADACHE were analyzed using a linear mixed model in which we addressed heterogeneity of time points by fitting the most appropriate model among compound symmetry, Huyhn Felt structure, and an unstructured covariance matrix (multivariate analysis of variance).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>F(5,34) = 3.17</method_desc>
            <param_type>eta^2</param_type>
            <param_value>0.37</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Headache Associated Morbidity Measured With MIDAS PAIN LEVEL After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) Will be Measured.</title>
        <description>We will determine how severely headache affect the patient's life before and after treatment by performing the Migraine Disability Assessment (MIDAS) questionnaire. MIDAS PAIN LEVEL is Item 7 which rates the 3-month average headache PAIN LEVEL on scale from 0 to 10 where 0 = no pain at all, and 10 = pain as bad as it can be.</description>
        <time_frame>Baseline (before treatment), and 6 weeks, 3 months, 6 months, 9 months, and 12 months after single dose intra-arterial Avastin (bevacizumab)</time_frame>
        <population>10 adult subjects presented with medically refractory radiation necrosis of the brain and disabling headache.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Intra-arterial Avastin (Bevacizumab)</title>
            <description>A single intra-arterial dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.&#xD;
25% Mannitol: Route of administration: In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.&#xD;
Low-dose Intra-arterial bevacizumab: Route of administration:&#xD;
In this study, the second step of the treatment will be administering intra-arterial bevacizumab into the appropriate cervical artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Headache Associated Morbidity Measured With MIDAS PAIN LEVEL After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) Will be Measured.</title>
          <description>We will determine how severely headache affect the patient's life before and after treatment by performing the Migraine Disability Assessment (MIDAS) questionnaire. MIDAS PAIN LEVEL is Item 7 which rates the 3-month average headache PAIN LEVEL on scale from 0 to 10 where 0 = no pain at all, and 10 = pain as bad as it can be.</description>
          <population>10 adult subjects presented with medically refractory radiation necrosis of the brain and disabling headache.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MIDAS PAIN LEVEL at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS PAIN LEVEL at 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS PAIN LEVEL at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS PAIN LEVEL at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS PAIN LEVEL at 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDAS PAIN LEVEL at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>To explore durability of clinical response, Migraine Disability Assessment (MIDAS) MIDAS PAIN LEVEL data were analyzed using a linear mixed model in which we addressed heterogeneity of time points by fitting the most appropriate model among compound symmetry, Huyhn Felt structure, and an unstructured covariance matrix (multivariate analysis of variance).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>F(5,35) = 3.96</method_desc>
            <param_type>eta^2</param_type>
            <param_value>0.3</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Headache Measured With Headache Impact Test (HIT-6) After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab)</title>
        <description>Quantitative change in headache will be assessed by performing the Headache Impact Test (HIT-6), which is a fixed-length 6-item questionnaire. The score for this questionnaire can range from 36 to 78, with 36 indicating minimum headache impact and the max score of 78 indicating worst possible headache impact.</description>
        <time_frame>Baseline (before treatment), and 6 weeks, 3 months, 6 months, 9 months, and 12 months after single dose intra-arterial Avastin (bevacizumab)</time_frame>
        <population>10 adult subjects presented with medically refractory radiation necrosis of the brain and disabling headache. All 10 received single treatment of low dose intra-arterial bevacizumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Intra-arterial Avastin (Bevacizumab)</title>
            <description>A single intra-arterial dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.&#xD;
25% Mannitol: Route of administration: In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.&#xD;
Low-dose Intra-arterial bevacizumab: Route of administration:&#xD;
In this study, the second step of the treatment will be administering intra-arterial bevacizumab into the appropriate cervical artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Headache Measured With Headache Impact Test (HIT-6) After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab)</title>
          <description>Quantitative change in headache will be assessed by performing the Headache Impact Test (HIT-6), which is a fixed-length 6-item questionnaire. The score for this questionnaire can range from 36 to 78, with 36 indicating minimum headache impact and the max score of 78 indicating worst possible headache impact.</description>
          <population>10 adult subjects presented with medically refractory radiation necrosis of the brain and disabling headache. All 10 received single treatment of low dose intra-arterial bevacizumab.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache Impact Test-6, Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.4" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Impact Test-6, 6 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Impact Test-6, 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Impact Test-6, 6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Impact Test-6, 9 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Impact Test-6, 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>To explore durability of clinical response, Headache Impact Test (HIT-6â¢) scores were analyzed using a linear mixed model in which we addressed heterogeneity of time points by fitting the most appropriate model among compound symmetry, Huyhn-Felt structure, and an unstructured covariance matrix (multivariate analysis of variance).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>F(5, 35) = 2.98</method_desc>
            <param_type>eta^2</param_type>
            <param_value>0.30</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Status After a Single Treatment of Low Dose Intra-arterial Bevacizumab</title>
        <description>Quantitative change in functional status will be assessed by performing Karnofsky Performance Status Scale (KPS). The KPS score can range from 0 to 100 where 0 is dead and 100 is fully alive and normal with no complaints and no evidence of disease.</description>
        <time_frame>Baseline (before treatment), Day 1, and at 3 months, and 12 months after single dose intra-arterial Avastin (bevacizumab)</time_frame>
        <population>10 adult subjects presented with medically refractory radiation necrosis of the brain and disabling headache. All were treated with steroids prior to study enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Intra-arterial Bevacizumab</title>
            <description>A single intra-arterial dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.&#xD;
25% Mannitol: Route of administration: In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.&#xD;
Low-dose Intra-arterial Bevacizumab: Route of administration:&#xD;
In this study, the second step of the treatment will be administering intra-arterial bevacizumab into the appropriate cervical artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Status After a Single Treatment of Low Dose Intra-arterial Bevacizumab</title>
          <description>Quantitative change in functional status will be assessed by performing Karnofsky Performance Status Scale (KPS). The KPS score can range from 0 to 100 where 0 is dead and 100 is fully alive and normal with no complaints and no evidence of disease.</description>
          <population>10 adult subjects presented with medically refractory radiation necrosis of the brain and disabling headache. All were treated with steroids prior to study enrollment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Karnofsky at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Karnofsky at Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Karnofsky at Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Karnofsky at Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>To explore durability of clinical response, Karnofsky Performance Status Scale (KPS) data were analyzed using a linear mixed model in which we addressed heterogeneity of time points by fitting the most appropriate model among compound symmetry, Huyhn-Felt structure, and an unstructured covariance matrix (multivariate analysis of variance).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>F(2,14) = 1.62</method_desc>
            <param_type>eta^2</param_type>
            <param_value>0.19</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Steroid Usage After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab)</title>
        <description>To assess the utility of intra-arterial (IA) bevacizumab treatment in allowing decreased steroid usage, total cumulative days of steroid usage were compared between the 12 months PRIOR TO and the 12 months IMMEDIATELY FOLLOWING IA bevacizumab. Days of steroid usage were tabulated via medical history and chart review at the baseline visit for the 12 months prior to IA bevacizumab and post-treatment on days 0 and 1, week 6, and months 3, 6, 9 and 12 for the 12 month total after IA bevacizumab treatment. Excluding topical steroid preparations, all days of enteral or parenteral steroid intake of any dose were included in the cumulative summation.</description>
        <time_frame>12 months prior to single dose of IA bevacizumab; 12 months following single dose of IA bevacizumab</time_frame>
        <population>10 adult patients age 31.0 (IQR 24.3, 42.8) years, including 8 (80%) women, 2 (20%) men, 9 (90%) white, 1 (10%) black, 9 (90%) Non-Hispanic, and 1 (10%) Hispanic</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Intra-arterial Avastin (Bevacizumab)</title>
            <description>A single intra-arterial dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.&#xD;
25% Mannitol: Route of administration: In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.&#xD;
Low-dose Intra-arterial bevacizumab: Route of administration:&#xD;
In this study, the second step of the treatment will be administering intra-arterial bevacizumab into the appropriate cervical artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Steroid Usage After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab)</title>
          <description>To assess the utility of intra-arterial (IA) bevacizumab treatment in allowing decreased steroid usage, total cumulative days of steroid usage were compared between the 12 months PRIOR TO and the 12 months IMMEDIATELY FOLLOWING IA bevacizumab. Days of steroid usage were tabulated via medical history and chart review at the baseline visit for the 12 months prior to IA bevacizumab and post-treatment on days 0 and 1, week 6, and months 3, 6, 9 and 12 for the 12 month total after IA bevacizumab treatment. Excluding topical steroid preparations, all days of enteral or parenteral steroid intake of any dose were included in the cumulative summation.</description>
          <population>10 adult patients age 31.0 (IQR 24.3, 42.8) years, including 8 (80%) women, 2 (20%) men, 9 (90%) white, 1 (10%) black, 9 (90%) Non-Hispanic, and 1 (10%) Hispanic</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 months PRIOR to IA bevacizumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" lower_limit="0" upper_limit="156.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months AFTER IA bevacizumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="0" upper_limit="87.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Wilcoxon signed rank test (2-sided) was used to compare the total number of days on steroids in the 12 months prior versus the 12 months immediately following single dose IA Avastin (bevacizumab).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.374</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Z = -0.889</method_desc>
            <param_type>Pearson's r</param_type>
            <param_value>-0.199</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Neurocognitive Change After Intra-arterial Bevacizumab</title>
        <description>In order to investigate post-operative changes in Neurocognitive performance after intra-arterial bevacizumab, patients who consented underwent formal neuropsychological battery testing. Sixteen subtests from the Neuropsychological Assessment Battery (Stern &amp; White, PAR Inc.) were chosen for brevity, sensitivity, and due to the wide range of available normative data (ages 18-97). For each subtest, T-score = 50 is the normative mean with SD = 10. Thus T-scores of 40-60 are within one standard deviation of the mean and are considered generally normal. Scores increasingly below 40 indicate decreased neurocognitive performance compared to healthy demographically matched persons. Scores significantly above 60 indicate increase neurocognitive performance compared to healthy demographically matched persons.</description>
        <time_frame>Baseline (before bevacizumab), and 3 months and 12 months after single dose intra-arterial Avastin (bevacizumab)</time_frame>
        <population>10 adult subjects, 2 male and 8 female, 1 black and 9 white, 1 Hispanic and 9 non-Hispanic, recruited from outpatient medical clinics at 2 academic medical centers (5 subjects per center) between Nov 2016 and Jan 2018. 2 subjects experienced progression of radiation necrosis requiring intervention at approx. month 11. Their 12-month data are not included in the Neurocognitive reporting.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Intra-arterial Bevacizumab</title>
            <description>A single intra-arterial dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.&#xD;
25% Mannitol: Route of administration: In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.&#xD;
Low-dose Intra-arterial Bevacizumab: Route of administration:&#xD;
In this study, the second step of the treatment will be administering intra-arterial bevacizumab into the appropriate cervical artery.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Neurocognitive Change After Intra-arterial Bevacizumab</title>
          <description>In order to investigate post-operative changes in Neurocognitive performance after intra-arterial bevacizumab, patients who consented underwent formal neuropsychological battery testing. Sixteen subtests from the Neuropsychological Assessment Battery (Stern &amp; White, PAR Inc.) were chosen for brevity, sensitivity, and due to the wide range of available normative data (ages 18-97). For each subtest, T-score = 50 is the normative mean with SD = 10. Thus T-scores of 40-60 are within one standard deviation of the mean and are considered generally normal. Scores increasingly below 40 indicate decreased neurocognitive performance compared to healthy demographically matched persons. Scores significantly above 60 indicate increase neurocognitive performance compared to healthy demographically matched persons.</description>
          <population>10 adult subjects, 2 male and 8 female, 1 black and 9 white, 1 Hispanic and 9 non-Hispanic, recruited from outpatient medical clinics at 2 academic medical centers (5 subjects per center) between Nov 2016 and Jan 2018. 2 subjects experienced progression of radiation necrosis requiring intervention at approx. month 11. Their 12-month data are not included in the Neurocognitive reporting.</population>
          <units>T score where mean T=50, SD=10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Digits Forward at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digits Forward at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digits Forward at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digits Backward at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digits Backward at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digits Backward at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Numbers &amp; Letters SPEED at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Numbers &amp; Letters SPEED at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Numbers &amp; Letters SPEED at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Numbers &amp; Letters Errors at BASELINE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Numbers &amp; Letters Errors at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Numbers &amp; Letters Errors at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Numbers &amp; Letters EFFICIENCY at Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Numbers &amp; Letters EFFICIENCY at 3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Numbers &amp; Letters EFFICIENCY at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naming at BASELINE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naming at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.9" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Naming at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>List Learning List Immediate Recall at BASELINE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>List Learning List Immediate Recall at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>List Learning List Immediate Recall at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>List Learning List Long Delayed Recall at BASELINE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>List Learning List Long Delayed Recall at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>List Learning List Long Delayed Recall at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shape Learning Immediate Recognition at BASELINE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shape Learning Immediate Recognition at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shape Learning Immediate Recognition at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shape Learning Delayed Recognition at BASELINE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shape Learning Delayed Recognition at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shape Learning Delayed Recognition at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Story Learning Phrase Unit Immediate Recall at BASELINE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Story Learning Phrase Unit Immediate Recall at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Story Learning Phrase Unit Immediate Recall at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Story Learning Phrase Unit Delayed Recall at BASELINE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Story Learning Phrase Unit Delayed Recall at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Story Learning Phrase Unit Delayed Recall at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Design Construction at BASELINE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Design Construction at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Design Construction at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mazes at BASELINE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mazes at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mazes at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Categories at BASELINE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Categories at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Categories at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.9" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Word Generation at BASELINE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Word Generation at 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Word Generation at 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>DIGITS FORWARD: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the DIGITS FORWARD variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.660</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 0.451</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.153</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>DIGITS BACKWARD: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the DIGITS BACKWARD variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.100</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 3.78</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.602</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>NUMBERS &amp; LETTERS SPEED: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the NUMBERS &amp; LETTERS SPEED variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.149</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 2.847</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.532</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>NUMBERS &amp; LETTERS ERRORS: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the NUMBERS &amp; LETTERS ERRORS variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.041</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 6.470</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.721</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>NUMBERS &amp; LETTERS EFFICIENCY: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the NUMBERS &amp; LETTERS EFFICIENCY variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.124</p_value>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F (2,5) = 3.256</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.566</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>NAMING: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the NAMING variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.898</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 0.110</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.042</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>LIST LEARNING LIST IMMEDIATE RECALL: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the LIST LEARNING LIST IMMEDIATE RECALL variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.754</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 0.299</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.107</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>LIST LEARNING LIST LONG DELAYED RECALL: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the LIST LEARNING LIST LONG DELAYED RECALL variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 7.556</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.751</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>SHAPE LEARNING IMMEDIATE RECOGNITION: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the SHAPE LEARNING IMMEDIATE RECOGNITION variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.426</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 1.018</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.289</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>SHAPE LEARNING DELAYED RECOGNITION: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the SHAPE LEARNING DELAYED RECOGNITION variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.326</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 1.412</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.361</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>STORY LEARNING PHRASE UNIT IMMEDIATE RECALL: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the STORY LEARNING PHRASE UNIT IMMEDIATE RECALL variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.790</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 0.247</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.090</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>STORY LEARNING PHRASE UNIT DELAYED RECALL: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the STORY LEARNING PHRASE UNIT DELAYED RECALL variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.505</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 0.786</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.239</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>DESIGN CONSTRUCTION: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the DESIGN CONSTRUCTION variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.080</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 4.362</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.636</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>MAZES: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the MAZES variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.052</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 5.654</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.693</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>CATEGORIES: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the CATEGORIES variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.968</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 0.033</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.013</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>WORD GENERATION: To explore post-operative change in Neurocognitive performance after intra-arterial bevacizumab, repeated measures ANOVA was performed for the WORD GENERATION variable across 3 time points (BL, 3 months, 12 months) where IQ was placed in the model as covariate.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.469</p_value>
            <p_value_desc>The threshold for statistical significance was p &lt; 0.05.</p_value_desc>
            <method>One way Repeat Meas ANOVA</method>
            <method_desc>F(2,5) = 0.884</method_desc>
            <param_type>partial eta^2</param_type>
            <param_value>0.261</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Adverse Event Monitoring performed on Day 0, Day 1, Week 6, Month 3, and Month 12</desc>
      <group_list>
        <group group_id="E1">
          <title>Low-dose Intra-arterial Bevacizumab</title>
          <description>A single intra-arterial dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.&#xD;
25% Mannitol: Route of administration: In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery.&#xD;
Low-dose Intra-arterial Bevacizumab: Route of administration:&#xD;
In this study, the second step of the treatment will be administering intra-arterial bevacizumab into the appropriate cervical artery.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v3.0 Term</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>Pt has history of chest pain but symptoms worsened and were associated with Month 6 episode of seizures</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Month 6 Pt 20 min non-responsive but appeared awake. Ambulance. Brain MRI decr edema no acute infarct or hemorrh. D/C home. Another Pt month 6 seizure activity w dizziness, chest pain, left jaw pain and left arm pain and numbness, double vision</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Acute encephalopathy</sub_title>
                <description>Pt admitted month 9 for 1-Confusion 2-Intermittent diaphoresis 3-Heat/cold intolerance 4-Mild abd Pain 5-Vomiting 6-Unsteadiness. Brain CT/MRI no sig change target area, age related ischemic changes. Workup neg. Meds held pt improved D/Ced home.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Double Vision</sub_title>
                <description>Double vision on Day 1 with dizziness reported after transferred into TCU per protocol. Investigator notified, patient transferred to ICU, symptoms resolved 2 hours after onset.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Month 9 Pt having recurrent worsening headaches, Brain MRI showed peri-lesion radiation necrosis with residual AVM. Pt opted for surgical resection of simple supra-tentorial AVM and Radiation necrosis in the Perisylvian and insular region.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Day 1 Double vision with dizziness reported after transferred into TCU per protocol. Investigator notified, patient transferred to ICU, symptoms resolved 2 hours after onset.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <description>Day 1 Pt developed acute onset Dysarthria followed by Lt. UE and LE Hemiparesis. Evaluated in ED, Brain CT/MRI and EEG revealed no sig changes, Hospitalized x 8 d started on steroids and Keppra (for poss seizure) weakness improved to LUE 5/5, LLE 3/5</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Left Lower Extremity Hemiparesis</sub_title>
                <description>Day 1 Pt developed acute onset Dysarthria followed by Lt. UE and LE Hemiparesis. Evaluated in ED, Brain CT/MRI and EEG revealed no sig changes, Hospitalized x 8 d started on steroids and Keppra (for poss seizure) weakness improved to LUE 5/5, LLE 3/5</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Left Upper Extremity Hemiparesis</sub_title>
                <description>Day 1 Pt developed acute onset Dysarthria followed by Lt. UE and LE Hemiparesis. Evaluated in ED, Brain CT/MRI and EEG revealed no sig changes, Hospitalized x 8 d started on steroids and Keppra (for poss seizure) weakness improved to LUE 5/5, LLE 3/5</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cerebral Edema</sub_title>
                <description>Month 8 Pt having symptoms of cerebral edema, Brain MRI showed interval increase in edema and radiation necrosis. Pt opted for 2 cycles of IV Avastin with subsequent improvement in symptoms and MRI findings.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v3.0 Term</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>1st degree AV block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Worsening chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner Ear pain</sub_title>
                <description>Right Inner Ear pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Steroid Induced Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Inability to focus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye twitches</sub_title>
                <description>Left eye twitches</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Homonymous Hemianopia</sub_title>
                <description>Left Homonymous Hemianopia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Loss of vision</sub_title>
                <description>loss of vision X 30 seconds</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vision loss in left eye</sub_title>
                <description>temporary vision loss in left eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Mild Abdominal Pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Generalized Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nosebleeds</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture Left Hand</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Head Trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Leg traumatic injury</sub_title>
                <description>Left leg traumatic injury</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ankle sprain due to fall</sub_title>
                <description>Right ankle sprain due to fall</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Traumatic Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical strain</sub_title>
                <description>Cervical strain due to MVA</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lower Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neck stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hip Pain</sub_title>
                <description>Right Hip Radiating Pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Knee pain</sub_title>
                <description>right knee pain from MVA</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Leg cramps</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Leg Muscle aches</sub_title>
                <description>Right Leg Muscle aches</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Partial toenail ingrown</sub_title>
                <description>Right partial toenail ingrown</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Mental Status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Expressive aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>1 episode Frontal Headache from MVA; 1 episode Headache; 1 episode Right sided headache; 1 episode Headaches with vertigo; 3 episodes worsening headache</description>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Inability to focus attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Increased dizziness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Numbness</sub_title>
                <description>1 episode Intermittent Numbness in the bottom; 1 episode Whole body numbness</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cold sensation leg</sub_title>
                <description>Right leg cold sensation knee to foot</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Calf muscle loss of tone</sub_title>
                <description>Rt Calf muscle loss of tone</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Generalized Seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tonic/clonic Seizures</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Shot term memory problems</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Trouble performing simple tasks</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Unsteadiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Visual seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Whole body shaking associated with seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Worsening of left sided weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Incomplete Spontaneous Abortion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Major Depressive Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Panic attacks</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Personality Changes</sub_title>
                <description>Personality Changes including anger</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <description>Acne Related to Decadron</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>hair loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Leg skin tear non-healing wound</sub_title>
                <description>Left Leg skin tear non-healing wound</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Scalp Pain</sub_title>
                <description>Left vertex scalp soreness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Worsening Acne on extremities</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Worsening of striae bilateral arms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral lower leg edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pilot Phase 2 Single Arm Clinical Trial with small number of patients. Not powered sufficiently to provide definitive proof for change in current standard of care of medically refractory radiation necrosis of the brain.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Shervin R. Dashti, MD, PhD, Principal Investigator</name_or_title>
      <organization>Norton Neuroscience Institute</organization>
      <phone>502-394-6390</phone>
      <email>shervin.dashti@nortonhealthcare.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

